Compare ACADIA Pharmaceuticals Inc. (ACAD) vs 8x8 Inc (EGHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs 8x8 Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while 8x8 Inc trades at $2.04 (market cap $279.31M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 16.1× 8x8 Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | EGHT | |
|---|---|---|
Market Cap | $4.49B | $279.31M |
Sector | Health | Technology |
52-Week High | $28.06 | $2.76 |
52-Week Low | $20.06 | $1.59 |
Enterprise Value | $3.69B | $556.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EGHT (8x8, Inc.) trades at $1.94, up 6.01% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 EPS versus $0.07 expected. Recent news highlights AI product launches and industry recognition, including being named a 2026 MetriStar Top Provider for CPaaS. However, the company reported a net loss of $27.21 million for 2025, though projections show potential profitability improvement in 2026.
The outlook remains cautiously optimistic with analyst consensus showing 39% buy ratings but mixed technical indicators. Key opportunities include continued AI product adoption and revenue growth momentum, while risks center on profitability challenges, high debt levels, and competitive pressures in the communications platform market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
